Evidence map›Paper›PMID 39118942›Full record

ReviewAnnals of translational medicine2024

Dendritic cell vaccination combined with irreversible electroporation for treating pancreatic cancer-a narrative review.

Zigeng Zhang, Guangbo Yu, Aydin Eresen, Zhilin Chen, Zeyang Yu, Vahid Yaghmai, Zhuoli Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Updates in Immunotherapy for Pancreatic Cancer.Journal of clinical medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zigeng Zhang *Department of Radiological Sciences, University of California Irvine, Irvine, CA, USA.
Guangbo Yu *Department of Biomedical Engineering, University of California Irvine, Irvine, CA, USA.
Aydin EresenDepartment of Radiological Sciences, University of California Irvine, Irvine, CA, USA.
Zhilin ChenDepartment of Human Biology and Business Administration, University of Southern California, Los Angeles, CA, USA.
Zeyang YuInformation School, University of Washington, Seattle, WA, USA.
Vahid YaghmaiDepartment of Radiological Sciences, University of California Irvine, Irvine, CA, USA.
Zhuoli ZhangDepartment of Radiological Sciences, University of California Irvine, Irvine, CA, USA.

Funding

MRI-Guided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic CancerR01CA209886 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Vahid Yaghmai, Zhuoli Zhang · 2016 to 2026
$3.3M
NCI NIH HHS R01 CA209886
6 · The paper itself

Abstract

Background and Objective: Pancreatic ductal adenocarcinoma (PDAC) is 3 Methods: We performed a literature search to identify studies focused on DC vaccine therapy and IRE ablation to boost therapeutic response against PDAC indexed in PubMed, Web of Science, and Scopus until February 20 Key Content and Findings: IRE ablation destructs tumor structure while preserving extracellular matrix and blood vessels facilitating local inflammation. The studies demonstrated IRE ablation reduces tumor fibrosis and promotes CTL tumor infiltration to PDAC tumors in addition to boosting immune response in rodent models. The administration of the DC vaccine following IRE ablation synergistically enhances therapeutic response and extends OS rates compared to the use of DC vaccination or IRE alone. Moreover, the implementation of data-driven approaches further allows dynamic and longitudinal monitoring of therapeutic response and OS following IRE plus DC vaccine immunoablation. Conclusions: The combination of IRE ablation and DC vaccine immunotherapy is a potent strategy to enhance the therapeutic outcomes in patients with PDAC.

Indexed as

Artificial intelligence (AI)cancer vaccinedendritic cell (DC)irreversible electroporation (IRE)pancreatic ductal adenocarcinoma (PDAC)

Identifiers

PMID39118942
PMCPMC11304422

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.